Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885412 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
A Phase 1 study of PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), sponsored by Rocket Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT05885412 is a Phase 1 study of PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) that is actively recruiting participants, run by Rocket Pharmaceuticals. The registered enrollment target is 9 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT05885412, a Phase 1 study of PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), is actively recruiting participants, sponsored by Rocket Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
Conditions Studied
Interventions
- GENETIC RP-A601
Study Locations (3)
California
- University of California, San Diego - La Jolla
North Carolina
- Duke University - Durham
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-08-29 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05885412
The ClinicalTrials.gov registry entry for NCT05885412 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rocket Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) appearing as the primary indexed condition, and to 1 intervention - of which RP-A601 is the first listed.
NCT05885412 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05885412 about?
NCT05885412 is a clinical study titled "A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)". This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
What is the current status of trial NCT05885412?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-08-29. Estimated completion is 2026-09.
What conditions does trial NCT05885412 study?
This clinical trial studies the following conditions: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM).
What interventions are being tested in trial NCT05885412?
The interventions under investigation include: RP-A601 (GENETIC).
Who is sponsoring clinical trial NCT05885412?
This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05885412 being conducted?
This trial has 3 study locations across California, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.